Prade Lars, Jones Andrew F, Boss Christoph, Richard-Bildstein Sylvia, Meyer Solange, Binkert Christoph, Bur Daniel
Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
J Biol Chem. 2005 Jun 24;280(25):23837-43. doi: 10.1074/jbc.M501519200. Epub 2005 Apr 19.
The malaria parasite Plasmodium falciparum degrades host cell hemoglobin inside an acidic food vacuole during the blood stage of the infectious cycle. A number of aspartic proteinases called plasmepsins (PMs) have been identified to play important roles in this degradation process and therefore generated significant interest as new antimalarial targets. Several x-ray structures of PMII have been described previously, but thus far, structure-guided drug design has been hampered by the fact that only inhibitors comprising a statine moiety or derivatives thereof have been published. Our drug discovery efforts to find innovative, cheap, and easily synthesized inhibitors against aspartic proteinases yielded some highly potent non-peptidic achiral inhibitors. A highly resolved (1.6 A) x-ray structure of PMII is presented, featuring a potent achiral inhibitor in an unprecedented orientation, contacting the catalytic aspartates indirectly via the "catalytic" water. Major side chain rearrangements in the active site occur, which open up a new pocket and allow a new binding mode of the inhibitor. Moreover, a second inhibitor molecule could be located unambiguously in the active site of PMII. These newly obtained structural insights will further guide our attempts to improve compound properties eventually leading to the identification of molecules suitable as antimalarial drugs.
疟原虫恶性疟原虫在感染周期的血液阶段,于酸性食物泡内降解宿主细胞血红蛋白。已鉴定出多种名为疟原虫天冬氨酸蛋白酶(PMs)的天冬氨酸蛋白酶在这一降解过程中发挥重要作用,因此作为新的抗疟靶点引发了极大关注。此前已描述了几种PMII的X射线结构,但迄今为止,结构导向的药物设计受到阻碍,因为仅发表了包含他汀部分或其衍生物的抑制剂。我们为寻找针对天冬氨酸蛋白酶的创新、廉价且易于合成的抑制剂所做的药物研发工作,产生了一些高效的非肽类非手性抑制剂。本文展示了PMII的高分辨率(1.6埃)X射线结构,其特征在于一种强效非手性抑制剂以前所未有的取向,通过“催化”水间接接触催化天冬氨酸。活性位点发生了主要侧链重排,这打开了一个新口袋,并允许抑制剂采用新的结合模式。此外,第二个抑制剂分子能够明确位于PMII的活性位点。这些新获得的结构见解将进一步指导我们改善化合物性质的尝试,最终导致鉴定出适合作为抗疟药物的分子。